Targeted proteomics of extreme vascular phenotypes in type 1 diabetes: the ESCAPER study
Authors' conclusion
In conclusion, escaping complications in long-term T1D appears to be associated with active molecular mechanisms. Progression is marked by apoptosis (Caspase-3), fibrosis (CHI3L1) and platelet activation (GP6), whereas resilience is associated with a distinct signature involving higher vWF and PON3.
Study context
- Population
- Patients with T1D with extreme vascular phenotypes
- Participants
- 92 vs 57
- Exposure
- Escapers vs Rapid Progressors
- Escapersn = 92
- Rapid Progressors (RP)n = 57reference
- Outcome
- Plasma proteins (Olink Cardiovascular panel III, 92 proteins), RP vs Escapers
Methodological detailstargeted proteomics (Olink Cardiovascular panel III, 92 proteins), extreme-phenotype comparison
- Targeted proteomics (Olink Cardiovascular panel III, 92 proteins)
- Extreme-phenotype comparison
Main finding
As reported in the abstract
- Higher in RP
- Adjusted difference (Caspase-3) + 2.12 NPX; P < 0.001
- Increased in RP
- Adjusted difference (Junctional Adhesion Molecule A) + 1.40 NPX; P < 0.001
- Increased in RP
- Adjusted difference (Glycoprotein VI, GP6) + 1.29 NPX; P < 0.001
- Increased in RP
- Adjusted difference (P-Selectin) + 0.82 NPX; P < 0.001
- Higher in RP
- Adjusted difference (Transferrin Receptor) + 0.53 NPX
- Higher in RP
- Adjusted difference (Fatty Acid Binding Protein 4) + 0.52 NPX
- Plasma proteins (Olink Cardiovascular panel III, 92 proteins), RP vs Escapers
- Adjusted difference (von Willebrand Factor) - 1.35 NPX; P < 0.001
- Plasma proteins (Olink Cardiovascular panel III, 92 proteins), RP vs Escapers
- Adjusted difference (Paraoxonase 3) - 0.34 NPX; P = 0.003
- Proteins differing significantly between RP and Escapers (FDR < 0.05)
- 20
- PECAM-1 also elevated
- + 0.55 NPX
- TNFRSF14 also elevated
- + 0.43 NPX
Observational data: associations, not effects.
Original publication
Targeted proteomics of extreme vascular phenotypes in type 1 diabetes: the ESCAPER study. Cardiovasc Diabetol. Published 20 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →